- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Nexavar
Synonyms :
sorafenib
Class :
Antineoplastic agents and Tyrosinase Kinase Inhibitor; VEGF Inhibitor
Dosage forms & Strengths
Tablet
200mg
400
mg
Oral
every 12 hrs
Tablet
In case of toxicity of the skin, reduce or discontinue the dose
400
mg
Oral
every 12 hrs
Tablet
In case of toxicity of the skin, reduce or discontinue the dose
sorafenib is indicated to treat metastatic or locally recurrent, differentiated, progressive thyroid cancer that shows refraction to radioactive iodine treatment
A dose of 400 mg orally is administered every 12 hours
In case of toxicity of the skin, reduce or discontinue the dose
Dose Adjustments
For differentiated thyroid cancer:
Dose reduction for dermatologic toxicities
1st dose reduction- reduce the dose to 600 mg/day
2nd dose reduction- 200 mg every 12 hours
3rd dose reduction- 200 mg per day
In the case of mild to moderate renal impairment, no dose adjustment is required
Dosing for severe renal impairment is not studied
In the case of mild to moderate hepatic impairment, no dose adjustment is required
Dosing for severe hepatic impairment is not studied
(Orphan)
Treatment of stage II B is through stage IV melanoma
(Orphan)
sorafenib is designated as orphan for the treatment of the above condition
The safety and efficacy of sorafenib are not seen in pediatric patients
Refer to the adult dosing
the drug is contraindicated in patients who have severe hypersensitivity to sorafenib or any other excipient of the formulation sorafenib should be used in combination with paclitaxel and carboplatin in the patients suffering from squamous lung cancer
may have an increased hepatotoxic effect when combined with sorafenib
the drug is contraindicated in patients who have severe hypersensitivity to sorafenib or any other excipient of the formulation sorafenib should be used in combination with paclitaxel and carboplatin in the patients suffering from squamous lung cancer
dasatinib may enhance the QTc-prolonging effect of QT-prolonging
may enhance the Qtc prolonging effect
may increase the hepatotoxic effect
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with doxepin-containing products
may increase the QTc-prolonging effect of QT-prolonging Agents
may increase the hepatotoxic effect of acetaminophen
may increase the hepatotoxic effect when combined
dronedarone: they may increase the QTc-prolonging effect of QTc-prolonging miscellaneous agents
gilteritinib: they may increase the QTc-prolonging effect of QTc-prolonging agents
halofantrine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
osimertinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
pentamidine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may enhance the QTc-prolonging effect of each other when combined
may enhance the QTc-prolonging effect of each other when combined
it increases the effect of myelosuppression in myelosuppressive agents
they decrease the concentration of sorafenib in serum
it increases the toxic/adverse effects of myelosuppressive agents
it decreases the concentration of sorafenib in serum
sorafenib increases the toxic/adverse effects of paclitaxel
UGT1A1 inhibitors increase the concentration of active metabolites of sacituzumab govitecan in serum
QTc interval is increased both by lenvatinib and sorafenib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of sorafenib
when used together, entrectinib and sorafenib both increase the QTc interval
when used together, encorafenib and sorafenib both increase the QTc interval
may have an increased QTc-prolonging effect when combined with levoketoconazole
may have an increased QTc-prolonging effect when combined with nilotinib
May increase the QTc-prolonging effect of QT-prolonging Agents
may increase the QTc-prolonging effect of QT-prolonging Agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
pazopanib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
quetiapine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ribociclib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
hypertensive agents may increase the hypertensive effect of androgens
it increases the toxic/adverse effect of myelosuppressive drugs
myelosuppressive agents increase the toxic/adverse effect of clozapine
it decreases the concentration of CYP3A4 substrates in serum
myelosuppressive agents increase the effect of myelosuppression of olaparib
it increases the effect of myelosuppression in myelosuppressive agents
it increases the effect of hypertension in hypertension-associated agents
sorafenib increases the effect of anticoagulation in warfarin
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
they increase the toxicity of bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
they increase the toxicity of bisphosphonate derivatives
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
sorafenib: they may diminish the serum concentration of CYP3A4 Inducers
sorafenib: they may diminish the serum concentration of CYP3A4 Inducers
sorafenib: they may diminish the serum concentration of CYP3A4 Inducers
sorafenib: they may diminish the serum concentration of CYP3A4 Inducers
sorafenib: they may diminish the serum concentration of CYP3A4 Inducers
interaction increases the serum concentration of docetaxel
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
angiogenesis Inhibitors may enhance the adverse/toxic effect of bisphosphonate derivatives
QT-prolongers increase the effect of QTc prolongation of haloperidol
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
it alters the QTc interval and increases the toxicity of sorafenib
sorafenib increases the efficacy of cocaine by altering the hepatic CYP2B6 enzyme metabolism
it increases the efficacy of sorafenib by altering the hepatic CYP3A4 enzyme metabolism
it increases the efficacy of sorafenib by altering the hepatic CYP3A4 enzyme metabolism
Actions and Spectrum: